CalciMedica, Inc. (NASDAQ:CALC - Get Free Report) CEO A. Rachel Leheny bought 20,000 shares of the firm's stock in a transaction dated Friday, November 1st. The shares were bought at an average price of $3.75 per share, with a total value of $75,000.00. Following the completion of the transaction, the chief executive officer now directly owns 130,926 shares in the company, valued at approximately $490,972.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
A. Rachel Leheny also recently made the following trade(s):
- On Tuesday, August 27th, A. Rachel Leheny acquired 1,000 shares of CalciMedica stock. The stock was acquired at an average price of $4.19 per share, with a total value of $4,190.00.
CalciMedica Price Performance
Shares of CALC opened at $3.51 on Friday. The company has a market capitalization of $37.73 million, a price-to-earnings ratio of -2.51 and a beta of 1.30. The business has a 50-day moving average of $4.25 and a 200-day moving average of $4.63. CalciMedica, Inc. has a 1 year low of $2.14 and a 1 year high of $8.38.
CalciMedica (NASDAQ:CALC - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.03. As a group, sell-side analysts anticipate that CalciMedica, Inc. will post -2.21 EPS for the current year.
Analyst Upgrades and Downgrades
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of CalciMedica in a research report on Tuesday, August 13th. Oppenheimer upped their price objective on CalciMedica from $14.00 to $20.00 and gave the company an "outperform" rating in a report on Wednesday, July 10th.
Check Out Our Latest Stock Analysis on CALC
Hedge Funds Weigh In On CalciMedica
An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc lifted its position in CalciMedica, Inc. (NASDAQ:CALC - Free Report) by 136.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,503 shares of the company's stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.
CalciMedica Company Profile
(
Get Free Report)
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
